Cellceutix Receives promulgation of Acceptance for state of matter 1 Clinical Trial MarketWatch (press release) Cellceutix owns the rights to viii drug compounds, including Kevetrin, which it is nonindustrial as a treatment for certain cancers, KM-133, for the treatment of disease of the skin , and KM-391, for the treatment of autism. More information is accessible on the ... and more » Link To Article
No comments:
Post a Comment